Antibodies against IGFR-like receptor and uses thereof

Patent metadata

Field	Value
Publication number	US-12583928-B2
Application number	US-202217679545-A
Country	US
Kind code	B2
Filing date	Feb 24, 2022
Priority date	Sep 7, 2015
Publication date	Mar 24, 2026
Grant date	Mar 24, 2026

Abstract

The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.

First claim

What is claimed is:

1 . An antibody or a fragment thereof which specifically binds to an IGFR-like receptor epitope, wherein said antibody or fragment thereof comprises complimentary determining regions (CDRs):

CDR-H1: 

(SEQ ID NO: 13 or 19)

SYHIS,

CDR-H2: 

(SEQ ID NO: 14 or 20)

AISSGGDTYYNSLLKS,

CDR-H3: 

(SEQ ID NO: 15 or 21)

ESY,

CDR-L1: 

(SEQ ID NO:16 or 22)

RASENIDTYLH,

CDR-L2: 

(SEQ ID NO: 17 or 23)

FASQSIS, and

CDR-L3: 

(SEQ ID NO: 18 or 24)

QQGNILPYT; or

CDR-H1: 

(SEQ ID NO: 25)

SYWMD,

CDR-H2: 

(SEQ ID NO: 26)

NIYPSDGETHYNQKFKD,

CDR-H3: 

(SEQ ID NO: 27)

LYSEYGS,

CDR-L1: 

(SEQ ID NO: 28)

KSSQSLLNSGNQKNYLT,

CDR-L2: 

(SEQ ID NO: 29)

WASTRDS, and

CDR-L3: 

(SEQ ID NO: 30)

QNDYSYPLT.

2 . The antibody or a fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

3 . The antibody or a fragment thereof of claim 1 , wherein the antibody fragment is any one of a dAb, an affibody, a Fab, a Fab′, a F(ab′)2, a Fv, a single chain Fv (scFv), a diabody, or a minibody comprising a scFv joined to a CH3 domain.

4 . The antibody or a fragment thereof of claim 1 , wherein the antibody specifically binds with an affinity of at least about 10 7 M −1 to an epitope of said IGFR-like receptor, the epitope comprising sequence:

(i) 

(SEQ ID NO.: 4)

MYKWAKPKICSEDLEG; 

(ii) 

(SEQ ID NO.: 6)

CTFSRNTPTRTFNY, 

or
(iii) both (i) and (ii).

5 . The antibody or a fragment thereof of claim 1 , wherein the antibody is a humanized antibody.

6 . The antibody or a fragment thereof of claim 1 , wherein the antibody comprises:
(i) a variable heavy chain amino acid sequence SEQ ID NO:31, and a variable light chain amino acid sequence SEQ ID NO:32, (ii) a variable heavy chain amino acid sequence SEQ ID NO:33, and a variable light chain amino acid sequence SEQ ID NO:34, or (iii) a variable heavy chain amino acid sequence SEQ ID NO:35, and a variable light chain amino acid sequence SEQ ID NO:36.

7 . The antibody or a fragment thereof of claim 1 , wherein the antibody comprises:
(i) a heavy chain amino acid sequence SEQ ID NO: 37, and a light chain amino acid sequence SEQ ID NO: 38, (ii) a heavy chain amino acid sequence SEQ ID NO: 39, and a light chain amino acid sequence SEQ ID NO: 40, or (iii) a heavy chain amino acid sequence SEQ ID NO: 41, and a light chain amino acid sequence SEQ ID NO: 42.

8 . The antibody or a fragment thereof of claim 1 , wherein the antibody specifically binds to an epitope of said IGFR-like receptor that is SEQ ID NO:1.

9 . The antibody or a fragment thereof of claim 1 , wherein the antibody specifically binds to an epitope of said IGFR-like receptor, the epitope comprising sequence:

(i)

(SEQ ID NO.: 4)

MYKWAKPKICSEDLEG;

and/or

(ii)

(SEQ ID NO.: 6)

CTFSRNTPTRTFNY.

Assignees

• Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh
• Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh

Inventors

• Lickert Heiko

Classifications

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• G01N2800/042

  Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism · CPC title